OS in patients without previous TBI by the presence or absence of measurable disease. Whereas almost all patients were in morphologic CR at transplantation, further data for “measurable disease” (flow cytometry, FISH, cytogenetics, or PET positivity) was available for 26 patients. These curves compare survival in patients with no measurable disease who had not previously received TBI (n = 13) to similar patients with measurable disease at transplantation (n = 6).